Koncentrering af STAT3 signalvejen i de fleste kræftformer: funktion af kunstige og rene hæmmere
Skilttransducere og aktivatorer af transkription (STAT’er) omfatter en husstand af cytoplasmatiske transkriptionskomponenter, som medierer intracellulær signalering, der normalt genereres ved cellegulvreceptorer og derved transmitterer den til kernen.
En hel del undersøgelser har vist konstitutiv aktivering af STAT3 i alle former for humane tumorer sammen med hæmatologiske maligne lidelser (leukæmi, lymfomer og et antal myelomer) ud over adskillige stabile tumorer (beslægtet med hoved og hals, bryst, lunge, mave) , hepatocellulære kræftformer, kræft- og prostatacancer.
Der er et robust bevis for at rådgive om, at afvigende STAT3-signalering fremmer initiering og udvikling af humane kræft ved både at hæmme apoptose eller inducere celleproliferation, angiogenese, invasion og metastase. Undertrykkelse af STAT3-aktivering fører til induktion af apoptose i tumorceller, og følgelig er dets farmakologiske modulation af tyrosinkinaseinhibitorer, antisense-oligonukleotider, lokke-nukleotider, dominerende ugunstige proteiner, RNA-interferens og kemoprevensive mæglere blevet anvendt til at undertrykke spredning af forskellige menneskelige mest kræftceller i tradition og tumorigenicitet in vivo.
elisa kits
Ikke desto mindre forbliver identifikationen og væksten af ny medicin, der kan målrette en dereguleret STAT3-aktivering, et nødvendigt videnskabeligt og medicinsk problem. Denne vurdering præsenterer beviset for væsentlige roller af STAT3 i onkogenese og diskuterer potentialet for vækst af nye flest kræftformerterapier baseret hovedsageligt på mekanistisk forståelse af STAT3-signaleringskaskade.
Description: A sandwich quantitative ELISA assay kit for detection of Human B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Rat B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Rat B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: BCL2L2 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 192 amino acids (1-172 a.a.) and having a molecular weight of 20.9kDa.;The BCL2L2 is fused to a 20 a.a His-Tag at N-terminus and purified by proprietary chromatographic techniques.
Description: BCL2L10 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 195 amino acids (1-172 a.a.) and having a molecular mass of 21.8kDa.;BCL2L10 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Description: BCL2L11 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 162 amino acids (1-138 a.a) and having a molecular mass of 18.5kDa.;BCL2L11 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Description: BCL2L1 Mouse Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 232 amino acids (1-209 a.a) and having a molecular mass of 25.8kDa. BCL2L1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag
Description: Matrix metalloproteinases (MMPs) are a family of endoproteases that require zinc and calcium for expressing catalytic activity. These enzymes play a central role in the maintenance and remodeling of the extracellular matrix. Elevated expression of their activity, caused either by up-regulation of their expression or down-regulation of their cognate inhibitors, has been implicated in various degenerative disorders, including arthritis, cardiovascular disease, skeletal growth-plate disorders, and cancer metastasis. MMP-2 is a secreted collagenase with specificity toward Type IV, V, VII, and X collagens. Recombinant human MMP-2 is a 62.0 kDa protein containing the entire catalytic N-terminal domain and the C-terminal domain (552 amino acids).
Description: The Trefoil Factor peptides (TFF1, TFF2 and TFF3) are expressed in the gastrointestinal tract, and appear to play an important role in intestinal mucosal defense and repair. TFF2 has been shown to inhibit gastrointestinal motility and gastric acid secretion. Recent data suggests a potential role for TFF2 in acute and chronic asthma (Nikolaidis, N.M. et al. Am. Journal Respir. Cell Mol. Biol. (2003) 4: 458-464). Recombinant human TFF2 is a 12.0 kDa polypeptide of 107 amino acid residues, which includes a 40-amino acid trefoil motif containing three conserved intramolecular disulfide bonds.
Description: Defensins (alpha and beta) are cationic peptides with a broad spectrum of antimicrobial activity that comprise an important arm of the innate immune system. The α-defensins are distinguished from the β-defensins by the pairing of their three disulfide bonds. To date, six human β-defensins have been identified; BD-1, BD-2, BD-3, BD-4, BD-5 and BD-6. β-defensins are expressed on some leukocytes and at epithelial surfaces. In addition to their direct antimicrobial activities, they can act as chemoattractants towards immature dendritic cells and memory T cells. The β-defensin proteins are expressed as the C-terminal portion of precursors and are released by proteolytic cleavage of a signal sequence and in some cases, a propeptide sequence. β-defensins contain a six-cysteine motif that forms three intra-molecular disulfide bonds. Recombinant human BD-2 is a 4.3 kDa protein containing 41 amino acid residues.
Description: Relaxin-2 is a peptide hormone structurally related to insulin, which is expressed in the placenta, decidua, prostate, and in the ovary during pregnancy. Of the three known relaxin genes, Relaxin-2 is the only relaxin known to circulate in the blood. Relaxin-2 binds specifically to the LGR7 and LGR8 receptors, previously identified as an “orphan” G protein coupled receptors. Signaling by Relaxin-2 through its target receptors enhances the growth of pubic ligaments and ripening of the cervix during birth. Recombinant Relaxin-2 is a nonglycosylated 6.0 kDa disulfide linked heterodimeric protein consisting of a 24 amino acid A-chain and a 29 amino acid B-chain.
Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa nonglycosylated intracellular protein which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein.
Først leveret til videnskabelig betragtning som infektiøse kræftfremkaldende mæglere praktisk talt 80 år i fortiden, er retrovirus i stil i moderne biologi af mange årsager.
(i) Virussens livscyklus indeholder et antal begivenheder – i eksplicit, omvendt transkription af det virale RNA-genom i DNA, ordnet integration af viralt DNA i værtskromosomer og anvendelse af værtsmekanismer til genekspression som respons på virale signaler- -som er stort set informative om eukaryote celler og vira.
(ii) Retroviral onkogenese er normalt afhængig af transduktion eller indsættelsesaktivering af mobile gener, og isolering af disse gener har tilbudt den videnskabelige gruppe med de fleste af de molekylære elementer, der nu er involveret i styringen af regelmæssig fremgang og hos de fleste kræftformer hos mennesker.
(iii) Retrovirus indeholder mange nødvendige veterinære patogener og to for nylig fundne humane patogener, de forårsagende mæglere af det erhvervede immundefekt syndrom (AIDS) og voksen T-celle leukæmi / lymfom.
(iv) Retrovirus er genetiske vektorer i naturen og kan modificeres til at fungere genetiske vektorer for hver eksperimentelle og terapeutiske funktioner.
(v) Indsættelse af retroviralt DNA i værtskromosomer kan anvendes til at markere cellelinier og til at fremstille udviklingsmutanter. Fremskridt inden for disse og forskellige områder inden for retrovirus-relateret biologi har været enorm gennem de foregående tyve år, men mange fornuftige og teoretiske problemer er dog stadig at løse.
IMGT, den verdensomspændende ImMunoGeneTics-database.
IMGT, den verdensomspændende ImMunoGeneTics-database, er en højkvalitets indbygget database, der specialiserer sig i immunoglobuliner (Ig), T-celle-receptorer (TcR) og Main Histocompatibility Complicated (MHC) molekyler af alle hvirveldyrarter, oprettet i 1989 af Marie-Paule Lefranc , Université Montpellier II, CNRS, Montpellier, Frankrig ([email protected]).
IMGT indeholder tre databaser: LIGM-DB, en komplet database over Ig og TcR, MHC / HLA-DB og PRIMER-DB (de sidste to i vækst); en enhed, IMGT / DNAPLOT, udviklet til sekvensevaluering og justeringer; og ekspertiseret viden baseret hovedsageligt på det IMGT-videnskabelige diagram, IMGT-repertoiret. Ved sin førsteklasses kvalitet og sin enkle videnfordeling har IMGT nødvendige implikationer i medicinsk analyse (repertoire i autoimmune sygdomme, AIDS, leukemier, lymfomer), terapeutiske tilgange (antistofudvikling), genomvariation og genomudviklingsforskning.
IMGT, det verdensomspændende ImMunoGeneTics datasystem.
Det verdensomspændende ImMunoGeneTics-datasystem (IMGT), oprettet i 1989, af Laboratoire d’ImmunoGenetique Moleculaire LIGM (Universite Montpellier II og CNRS) i Montpellier, Frankrig, er en indbygget informations nyttig ressource af høj kvalitet, der er specialiseret inden for immunoglobulinerne (IGs) ), T-cellereceptorer (TR’er), kompliceret histokompatibilitet kompliceret (MHC) for humane og forskellige hvirveldyr og associerede proteiner fra immunprogrammerne (RPI), der hører til immunglobulinsuperfamilien (IgSF) og til MHC superfamilien (MhcSF).
IMGT indeholder et antal sekvensdatabaser (IMGT / LIGM-DB, IMGT / PRIMER-DB, IMGT / PROTEIN-DB og IMGT / MHC-DB), en genomdatabase (IMGT / GENE-DB) og en tredimensionel (3D ) konstruktionsdatabase (IMGT / 3Dstructure-DB), internetkilder omfattende 8000 HTML-sider (IMGT).
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: Bcl-2 Des BH4 domain (10-30 residues) Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 197 amino acids 1-9 and 31-218.;The Bcl-2 is expressed as His-Tag fusion protein and purified by proprietary chromatographic techniques.
Description: BCL7A Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 233 amino acids (1-210 a.a.) and having a molecular mass of 25.2kDa (Molecular size on SDS-PAGE will appear higher).;BCL7A is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
BCL7C B-cell CLL/lymphoma 7C Human Recombinant Protein
Description: BCL7C Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 240 amino acids (1-217 a.a) and having a molecular mass of 25.9kDa (Molecular size on SDS-PAGE will appear higher).;BCL7C is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
BCL10 B-cell CLL/Lymphoma 10 Human Recombinant Protein
Description: BCL10 Human Recombinant produced in E. coli is a single polypeptide chain containing 257 amino acids (1-233) and having a molecular mass of 28.8kDa (molecular weight on SDS-PAGE will appear higher).;BCL10 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
BCL2 Human, B-Cell Lymphoma Protein 2 Alpha Human Recombinant Protein, His Tag
Description: BCL2 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing amino acids 1-211 and having a molecular mass of 25.4 kDa. The BCL2 is fused to a 20 a.a. His-Tag at N-terminus and purified by proprietary chromatographic techniques.
Bcl-2 B-Cell Leukemia/Lymphoma 2, (1-206 a.a.) Human Recombinant Protein
Description: Bcl-2 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing amino acids 1-206._x000D_ The wild type Bcl-2 is missing 12 amino acids from C-terminus. C-terminus is fused to His-Tag. C-terminus his-tag, mimics the deleted C-terminus membrane domain thus maintaining its biological activity. _x000D_ Bcl-2 is purified by proprietary chromatographic techniques._x000D_
Description: Activin B is a TGF-β family member that exhibits a wide range of biological activities including regulation of embryogenesis, osteogenesis, hematopoiesis, reproductive physiology and hormone secretion from the hypothalamic, pituitary and gonadal glands. Activin B, like certain other members of the TGF-β family, signals through the ActRII receptor (Activin Receptor type II). Human Activin B is a 25.6 kDa disulfide-linked homodimer consisting of two βB chains, each containing 115 amino acid residues. *Manufactured using BTI-Tn-5B1-4 cells under license from the Boyce Thompson Institute for Plant Research, Inc
BMP-7 modvirker TGF-beta1-induceret epitel-til-mesenkym overgang og vender kronisk nyreskade Knoglemorfogent protein (BMP) -7 er et 35-kDa homodimert protein og et[...]
Multinationalt studie af effektiviteten og sikkerheden af humaniseret monoklonalt anti-HER2-antistof hos kvinder, der har HER2-overudtrykkende metastatisk brystkræft, som er udviklet[...]
